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Burkholderia cenocepacia is a major concern for people suffering from cystic fibrosis as
it contributes to serious respiratory tract infections. The lack of drugs effective against
this opportunistic pathogen, along with the high level of resistance to multiple antibiotics,
render the treatment of these infections particularly difficult. Here a new compound,
belonging to the 2,1,3-benzothiadiazol-5-yl family (10126109), with a bactericidal effect
and a minimal inhibitory concentration (MIC) of 8 μg/ml against B. cenocepacia, is
described. The compound is not cytotoxic and effective against B. cenocepacia clinical
isolates and members of all the known B. cepacia complex species. Spontaneous
mutants resistant to 10126109 were isolated and mutations in the MerR transcriptional
regulator BCAM1948 were identified. In this way, a mechanism of resistance to this new
molecule was described, which relies on the overexpression of the RND-9 efflux pump.
Indeed, rnd-9 overexpression was confirmed by quantitative reverse transcription PCR,
and RND-9 was identified in the membrane fractions of the mutant strains. Moreover,
the increase in the MIC values of different drugs in the mutant strains, together with
complementation experiments, suggested the involvement of RND-9 in the efflux of
10126109, thus indicating again the central role of efflux transporters in B. cenocepacia
drug resistance.
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Introduction
Burkholderia cenocepacia, together with B. multivorans, contributes to serious respiratory tract
infections in people suﬀering from cystic ﬁbrosis (CF; LiPuma, 2010). Worldwide about 80000
people are aﬀected by CF, with a life expectancy of about 50 years; a proven eﬀective therapy
aimed at correcting the basic genetic defect is still lacking (Dodge et al., 2007). The disease causes
the formation of thick and sticky mucus especially in the lungs, leading to serious infections
that in 2009 in Europe accounted for the 45% of CF deaths1. In particular, B. cenocepacia is
one of the worst CF-associated pathogens, as it carries the greatest risk of mortality, and it
can lead to a fatal pneumonia called the “cepacia syndrome.” Moreover, the low percentage
of post-transplantation survival among B. cenocepacia infected patients makes the infection
due to this bacterium a contraindication for transplantation in most hospitals (Noone, 2008;
1https://www.ecfs.eu/projects/ecfs-patient-registry/annual-reports
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De Soyza et al., 2010). Finally, due to its high level of resistance
tomost antibiotics (aminoglycosides, polymyxins, and β-lactams)
it is particularly diﬃcult to eradicate (Saiman et al., 2003).
Accordingly, treatment of B. cenocepacia infections is often
unsuccessful and triple antibiotic combination therapy is only
aimed at decreasing bacterial load (Aaron et al., 2000).
Active transport is now recognized as a major cause
of antimicrobial resistance in bacteria (Higgins, 2007).
In B. cenocepacia the transporters belonging to the RND
(Resistance-Nodulation-Cell Division) family are encoded
by 16 operons (Perrin et al., 2013). We previously showed,
by gene inactivation, the importance of RND-3 (BCAL1674-
76) and RND-4 (BCAL2820-22) in the intrinsic resistance
of B. cenocepacia J2315 as well as their involvement in the
accumulation of quorum sensing molecules in the medium
(Buroni et al., 2009). More recently, RND-4 has also been
shown to be responsible for the resistance to a new antitubercular
thiopyridine compound eﬀective against B. cenocepacia (Scoﬀone
et al., 2014). In another recent work, the eﬀect of the deletion
of the 16 RND operons was evaluated both in planktonic and
sessile cells (Buroni et al., 2014). In particular, RND-3 and
RND-4 have been shown to play a major role in the resistance
to various antimicrobial drugs in planktonic B. cenocepacia
J2315, while RND-3, RND-8, and RND-9 were needed to protect
sessile cells against tobramycin or ciproﬂoxacin (Buroni et al.,
2014).
In this study, a new molecule eﬀective against B. cenocepacia
J2315 is described. The compound belongs to the 2,1,3-
benzothiadiazol-5-yl family and was named 10126109.
A mechanism of resistance to this new molecule is described,
which relies on the overexpression of the RND-9 eﬄux pump,
thus indicating, once again, the central role of eﬄux transporters
in B. cenocepacia drug resistance.
Materials and Methods
Bacterial Strains and Growth Conditions
Burkholderia cenocepacia strains and B. cepacia complex (Bcc)
species were grown in Luria-Bertani (LB) medium (Difco), with
shaking at 200 rpm, or on LB agar, at 37◦C. B. cenocepacia J2315
was used as the wild-type (WT) strain.
Synthesis of Methyl [(4-nitro-2,1,3-
benzothiadiazol-5-yl)thio]acetate
(10126109)
Solution of 1.43 g (10 mmol) of 2-amino-4-chloroaniline in the
mixture of 5.4 ml thionyl chloride and 0.35 ml of concentrated
sulfuric acid was reﬂuxed for 1 h. The reaction mixture was
cooled to 35◦C, mixed with 4.3 ml of concentrated sulfuric acid
and stored for 20 min. This solution was treated by mixture of
1.43 ml (32 mmol) fumigating nitric acid and 2.2 ml concentrated
sulfuric acid at 20–25◦C for 10 min. The reaction mixture was
stored at 25–30◦C for 30 min and poured to ice water. Gray
precipitate was ﬁltered oﬀ, washed by water and methanol and
recrystallised frommethanol. The yield of 5-chloro-4-nitro-2,1,3-
benzothiadiazole is 1.6 g (74%). mp: 145–147◦C.
Suspension of 0.5 g (2.32 mmol) of 5-chloro-4-nitro-2,1,3-
benzothiadiazole, 0.32 ml (3.5 mmol) of methyl mercaptoacetate
and 0.45 g (3.5 mmol) of potassium carbonate in 25 ml of
acetonitrile was stored for 30 min at room temperature. The
reaction mixture was poured in 100 ml of cold water and yellow
precipitate was ﬁltered oﬀ. The yield of methyl [(4-nitro-2,1,3-
benzothiadiazol-5-yl)thio]acetate is 0.17 g (24%). mp: 121–123◦C
(methanol); MS (m/z): 285 (M+); 1H NMR (DMSO-d6): δδ 8.22
(1H, d, J = 8.1 Hz, CH), 7.67 (1H, d, J = 8.8 Hz, CH), 3.89 (2H,
s, CH2), 3.71 (3H, s, CH3) ppm. Anal. C9H7N3O4S2, C,H,N.
Determination of Cytotoxicity
HeLa Ohio cells were seeded at 2.4 × 104 cells/well in 96-
well ﬂat-bottomed microtiter plates. To determine the 50%
cytotoxic concentration (CC50), 2-days-old conﬂuent HeLa
cell monolayer were incubated with serial dilutions (factor 2,
each concentration in duplicate) of the 10126109 compound
for 72 h (37◦C, 5% CO2). Then, the cells were ﬁxed and
stained with a crystal violet formalin solution. Cytotoxicity
was quantiﬁed spectrophotometrically with a plate reader as
described previously (Schmidtke et al., 2001).
The potential mutagenicity was assessed using the SOS-
chromotest at 50 μM as previously described (Quillardet et al.,
1982).
Minimal Inhibitory Concentrations (MIC)
Determination
The eﬀectiveness of 10126109 compound against B. cenocepacia
J2315, B. cenocepacia clinical isolates and Bcc species, was
assessed determining MICs. The experiment was performed
with the twofold microdilution method in U-bottom 96-
well microtiter plates, and inoculating about 105 CFU in LB
medium, using concentrations ranging from 1 to 256 μg/ml.
The microtiter plates were incubated at 37◦C for 2 days and
growth was determined by the resazurin method (Martin et al.,
2006). A solution of resazurin sodium salt (Sigma–Aldrich) was
prepared at 0.01% in distilled water and ﬁlter-sterilized. 30 μL
of resazurin solution were added to each well after 2 days of
incubation at 37◦C, and the microtiters were reincubated at
the same temperature for about 4 h. The MIC was deﬁned as
the lowest concentration of the drug that prevented a change
in color from blue to pink, which indicates the growth of
bacteria.
The same results were conﬁrmed also by streaking 1 × 104
cells onto LB agar containing twofold dilutions of the drug.
To obtain the resistance proﬁle of B. cenocepacia mutants,
the following compounds, at concentrations ranging from 2
to 256 μg/ml, were tested: chloramphenicol, ciproﬂoxacin,
levoﬂoxacin, nalidixic acid, norﬂoxacin, and sparﬂoxacin.
All antibiotics were purchased from Sigma–Aldrich. In
all experiments the results represent the average of three
independent replicates.
Time-Killing Curve
Time-killing curve of B. cenocepacia J2315 toward 10126109 was
performed by the broth macrodilution method, as described by
Silva et al. (2011). Brieﬂy, 0.5, 1, 2, and 4 multiples of the MIC
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(8 μg/ml) were used. 20 ml of LB broth with the appropriate
10126109 concentrations were inoculated with exponentially
grown B. cenocepacia cells, to yield a ﬁnal concentration of
approximately 1 × 107 CFU per ml. The cultures were incubated
at 37◦C, and aliquots were removed at 0, 2, 4, 6, 8, 24,
28, and 32 h for the determination of viable counts. Serial
dilutions were spread on LB solid medium and the plates were
incubated at 37◦C for 2 days. Then the number of colonies was
determined.
Killing curves were constructed by plotting the log10 CFU
ml−1 vs. time. Bactericidal activity was deﬁned as a reduction
of 99.9% (≥3 log10) of the total number of CFU ml−1 in the
original inoculum (NCCLS, 1999). Bacteriostatic activity was
deﬁned as maintenance of the original inoculum concentration
or a reduction of less than 99.9% (<3 log10) of the total number
of CFU ml−1 in the original inoculum.
Isolation of B. cenocepacia Mutants Resistant
to 10126109
Burkholderia cenocepacia resistant mutants were isolated by
plating about 109 CFU of WT culture on LB agar, containing
diﬀerent concentrations of 10126109 compound, ranging from
4 to 20-fold the MIC. Plates were incubated at 37◦C for at least
3 weeks. The resistance proﬁle of each strain was conﬁrmed by
growing the colonies in liquid LB medium containing the same
concentration of molecule at which the strains were isolated, and
re-streaking the cells onto solid medium containing 10126109.
Genomic DNA Extraction and Sequencing
Genomic DNA was extracted from B. cenocepacia J2315 and
spontaneous mutants using Bacteria DNA Preparation Kit (Jena
Bioscience). 109 cells were harvested by centrifugation and
treated as described in the manufacturer’s protocol. The DNA
was resuspended in Tris-EDTA (TE) and used for sequencing
purpose. Quality and concentration of each sample were assessed
using spectrophotometer and agarose gel electrophoresis. All
genomes were sequenced through Illumina Solexa technology
(IGA Technology Service Srl). Reads quality was assessed using
FastQC toolkit2. Reads trimming was performed using the
dynamic trimming approach implemented in SolexQA (Cox
et al., 2010), using a Phred score of 30 as the base call quality
threshold. Trimmed reads were then mapped on the reference
genome using Mosaik aligner with default parameters (Lee et al.,
2014). Only those SNPs that (i) were not present in the WT
strain, (ii) were supported by, at least, eight reads, and (iii)
had a support greater than 70% were considered for further
analysis. SNPs calling was performed using VarScan (Koboldt
et al., 2009).
Mutations were conﬁrmed by sequencing PCR amplicons
using the following primer pairs with HotStar HiFidelity
Polymerase kit (Qiagen): BCAM1948FOR (5′-ATGGGTATCC
AGGAAACC-3′) and BCAM1948REV (5′-GAGTCGCTGCAG
TTCCTCGA-3′) for SB5 and SB36 mutants; BCAM1948SB34F
(5′-AAATCGCCGAGCAGCTCGTCAGC-3′) and BCAM194
8SB34R (5′-AGCCGGACGACATCGCGGACGC-3′) for SB34
2http://www.bioinformatics.babraham.ac.uk/projects/fastqc/
mutant; BCAM1948SB6F (5′-TAAACTGCCGCGTAGCAT-3′)
and BCAM1948REV for SB6 mutant.
RNA Purification and Reverse Transcription
(RT)
For the Quantitative reverse transcription PCR (qRT-PCR)
experiment, WT and mutant B. cenocepacia cells (1 × 109 CFU)
were collected by centrifugation. Total RNA was extracted
using the RiboPure Bacteria Kit (Ambion), following the
manufacturer’s instructions. A 30 min incubation of each
sample with DNase I (Ambion) was performed, following
the manufacturer’s protocol. RNA quality and concentration
were assessed using both agarose gel electrophoresis and
the spectrophotometric determination. One-microgram of total
RNAwas used for cDNA generation using the QuantiTect reverse
Transcription kit (Qiagen) according to the manufacturer’s
instructions, but diluting the cDNA 1:2 before using for
qRT-PCR.
Quantitative Reverse Transcription PCR
(qRT-PCR)
For each strain, qRT-PCR experiments on BCAM1946 gene were
performed. The following primers were used: BCAM1946Rtfor
(5′-TGCTCGTCGTGATCCTGTTT-3′) and BCAM1946Rtrev
(5′-CGAACAGCGTGAGCGTATTG-3′). All reactions were
performed on a Rotor-Gene-6000 cycler (Corbett), using
Quanti-Tect SYBR Green PCR Kit (Qiagen), according to
manufacturer’s instructions. Fifteen-microliter were used as a
ﬁnal volume for each reaction. Cycling conditions were: 95◦C
for 15 min (1 cycle), 94◦C for 15 s followed by 54◦C for 30 s
and 72◦C for 30 s (40 cycles). A melting curve analysis was
included at the end of each run. Each sample was spotted in
triplicate and a reference gene, as well as control samples without
cDNA, were included in each experiment. BCAM0918 (rpoD)
gene was used as reference gene with the following primers:
0918F (5′-GCCAACCTGCGTCTCGT-3′) and 0918R (5′-
AACTTGTCCACCGCCTT-3′), using an annealing temperature
of 50◦C. The fold diﬀerence in gene expression between the
mutants and the WT was assessed using the comparative
Ct-method (Livak and Schmittgen, 2001). The results are
the average of three independent replicates. To determine
if diﬀerences in expression were signiﬁcant (P < 0.05) the
Mann–Whitney test was used.
Complementation
For complementation experiments the entire BCAM1948 gene
was PCR ampliﬁed from B. cenocepacia J2315 genomic
DNA using primers 1948compF (5′-TTCATATGTAAACTG
CCGCGTAGCAT-3′) and 1948compR (5′-TTGGATCCCGT
CATTCGCAATCGGTC-3′). The resulting PCR product was
digested with NdeI and BamHI (restriction sites are underlined
in the primer sequences) and cloned into pSCrhaB2 (Cardona
and Valvano, 2005; kindly provided by Prof. M. Valvano) that had
been treated with the same restriction endonucleases.
The recombinant vector was then introduced into
B. cenocepacia resistant mutants by conjugation via a
triparental mating, as previously described (Craig et al.,
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1989). The expression of BCAM1948 was induced by adding
rhamnose (0.2%) to the LB medium. The MIC of 10126109,
chloramphenicol, ciproﬂoxacin, levoﬂoxacin, nalidixic acid,
norﬂoxacin, and sparﬂoxacin were determined for both the
mutant strains transformed with the empty vector and for
the same strains carrying the BCAM1948/pSCrhaB2 vector,
all grown in LB medium in the presence of trimethoprim
(800 μg/ml) and 0.2% (w/V) rhamnose.
Results
Identification of a New Compound with
Antimicrobial Activity Against B. cenocepacia
More than 100 compounds from an in-house collection and
shown to be eﬀective against other bacteria were tested for their
eﬃcacy against B. cenocepacia J2315. For each compound, the
MIC was evaluated through the twofold microdilution method
(Martin et al., 2006); only a compound belonging to the 2,1,3-
benzothiadiazol-5-yl family (named 10126109, Figure 1), was
found to have a promising antibacterial activity, showing a MIC
of 8 μg/ml against B. cenocepacia J2315 (Table 1).
Cytotoxicity of the lead compound 10126109 was determined
on HeLa cells and shown a 50% cytotoxic concentration
(CC50) > 100 μM. The compound was also tested for its
FIGURE 1 | Chemical structure of 10126109 compound.
TABLE 1 | Antimicrobial susceptibilities (µg/ml) of Burkholderia
cenocepacia J2315, of 10126109 resistant mutants, and of the
complemented mutants.
B. cenocepacia
strains
Compound MIC (µg/ml)
10126109 CHL CIP LVX NAL NOR SPX
J2315 8 32 4 4 16 16 8
SB5 128 64 32 32 256 128 64
SB6 128 64 32 32 256 128 64
SB34 256 64 32 32 256 128 64
SB36 256 64 32 64 256 128 128
SB5/pSCrhaB2 64 64 32 16 256 128 64
SB5/pSCrhaB2-1948 16 32 16 16 32 32 16
SB34/pSCrhaB2 64 64 32 16 256 128 64
SB34/pSCrhaB2-1948 8 32 8 8 32 32 16
SB36/pSCrhaB2 128 64 64 32 256 128 64
SB36/pSCrhaB2-1948 8 32 8 8 32 32 16
CHL, chloramphenicol; CIP, ciprofloxacin; LVX, levofloxacin; NAL, nalidixic acid;
NOR, norfloxacin; SPX, sparfloxacin.
potential mutagenicity using the SOS-chromotest at 50 μM
and the test was negative. 10126109 has good pharmacokinetic
properties, low toxicity and a scaﬀold already used in commercial
compounds (e.g., Tizanidine hydrochloride).
In order to assess if 10126109 exerts a bacteriostatic or a
bactericidal eﬀect on Burkholderia cells, a time-kill curve was
constructed using concentrations ranging from 0.5 to 4 times the
MIC value (Figure 2). A bactericidal eﬀect was observed using
two and fourfold the MIC of 10126109 (i.e., a reduction of 99.9%
(≥3 log10) of the total number of CFU ml−1 in the original
inoculum was observed), while the number of B. cenocepacia
cells remained constant when an amount of compound equal
to the MIC was added to the culture. These data suggest that
bacterial killing is concentration dependent, as already reported
for ciproﬂoxacin (Silva et al., 2011).
To assess if 10126109 is active against clinical circulating
strains, the compound was tested against 30 B. cenocepacia
clinical isolates (belonging to genomovars III-A, III-B, and III-
D). All the strains resulted to be susceptible to 10126109, with
MIC values ranging from <2 to 32 μg/ml, except three strains
belonging to genomovar III-B, which showed MICs of 64–
256 μg/ml (Supplementary Table S1). These data provide a good
starting point for pre-clinical trials.
Subsequently, the compound was tested also against members
of all the other Bcc species (Supplementary Table S2), showing
MIC values ranging from 8 μg/ml (B. ambifaria, B. anthina,
B. arboris, and B. lata) to 32 μg/ml (B. stabilis, B. ubonensis, and
B. vietnamiensis).
Isolation and Characterization of Spontaneous
Mutants Resistant to 10126109
To isolate spontaneous resistant mutants in an attempt to ﬁnd
the 10126109 target(s), B. cenocepacia J2315 cells were spread on
plates containing 4–20-fold the MIC of the compound.
Two spontaneous mutants isolated through direct selection
onto solid medium containing 64 μg/ml of the benzothiadiazol
derivative (eightfold the MIC), and two additional mutants,
isolated from plates containing LB plus 128 μg/ml of the
compound (16-fold the MIC) were selected for further
characterization. These mutant strains were named SB5,
SB6, SB34, and SB36, respectively, and the resistance phenotype
was conﬁrmed for all the mutants (Table 1). The mutation
frequency was about 4 × 10−9.
The genomic DNA of mutant strains was then extracted
and sequenced by Illumina Solexa method (IGA Technology
Services, Udine) with the aim to understand which mutations
were responsible for the resistance proﬁle. The only gene
resulting mutated in all the strains was BCAM1948. It
encodes a 159 amino acid protein, which belongs to the
MerR family of transcriptional regulators. As it is located
immediately downstream from the BCAM1945–BCAM1947
operon, encoding the putative quinoxaline eﬄux system
transporter, previously named RND-9 (Bazzini et al., 2011), we
hypothesized that this protein controls the expression of the
eﬄux system.
The mutation identiﬁed in SB5 strain was the substitution
C58T causing arginine-20 to be replaced by a cysteine residue. In
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FIGURE 2 | Time-kill curve of Burkholderia cenocepacia J2315 exposed to 10126109. A B. cenocepacia J2315 culture in exponential phase of growth (•)
was split and concentrations of 10126109 corresponding to 0.5 (©), 1 (), 2 (), and 4-fold () the MIC value were added. The viable counts were determined at
37◦C during 32 h. The dotted line indicates a reduction of 3 log10.
the SB36 resistant mutant, C-58 was changed into an A, leading
to the replacement of arginine-20 with a histidine residue.
In SB6 mutant, the mutation was located in the intergenic
region between BCAM1947 and BCAM1948, where A-49 is
deleted. Interestingly, this deletion is located in a palindromic
sequence (5′-ttgaagttaacttcaa-3′).
In SB34 mutant, the mutation was the substitution T380C,
which led to the amino acid change Leu-153→Pro, having the
two amino acids completely diﬀerent chemical properties.
PCR ampliﬁcation and sequencing were performed as
described in Section “Materials and Methods” and conﬁrmed the
presence of the respective mutations in the genome of the four
mutant strains.
Furthermore, we analyzed the evolutionary conservation and
the possible functional consequences of the mutations falling
within the coding region of BCAM1948. First, we checked
the conservation of Arg-20 and Leu-153 in closely related
microbes by aligning the best 30 BLAST hits (probing the NCBI
non-redundant database) of the BCAM1948 encoded protein.
A close inspection of this multialignment revealed that the Arg-
20 was conserved throughout all the analyzed genomes (see
Supplementary Figure S1), suggesting the presence of some
functional constraints acting in this position. Next, we checked
the location of the mutated amino acids on the three-dimensional
structure of the encoded protein. A search in Swiss Model
Expasy (Biasini et al., 2014), revealed that the closest structural
template of the MerR–like transcriptional regulator encoded by
BCAM1948 is the (2Fe-2S) oxidative-stress sensor SoxR from
Escherichia coli (STML id: SMTL id: 2zhh.1, Watanabe et al.,
2008). The region (aa 1–80) embedding this residue (which
resulted to be located at the accessible molecular surface) is
predicted to be a DNA-binding domain. Interestingly, it has
been shown that changes in the residues embedded in this
region may lead to changes in the relative positions of all their
protein subunits (5-helix, the DNA-binding domain and the Fe-S
binding domain) and that the proper arrangement of the DNA-
binding domain is essential for correct redox signal transduction
(Watanabe et al., 2008). In particular, a change identical to the
one identiﬁed in B. cenocepacia J2315 in this work (Arg-20→Cys)
has been already observed in E. coli (Hidalgo et al., 1997), where
it leads to an altered redox phenotype. Accordingly, we here
speculate that the most likely consequence of the changes in the
Arg-20 position in B. cenocepacia J2315 mutants is an impaired
redox activity of the BCAM1948 encoded protein.
Unfortunately, the other mutation in BCAM1948 (Leu-
153→Pro) falls in a region showing no homology with other
known 3D structures of MerR-like proteins and thus it is not
possible to infer any feature of the altered phenotype resulting
from this mutation in B. cenocepacia J2315.
Expression Analysis of RND-9
As the mutations responsible for the resistance to 10126109
were located in the gene encoding the transcriptional regulator
BCAM1948, to determine whether this phenotype was associated
with a diﬀerential expression of RND-9 system, quantitative
RT-PCR experiments were performed. The expression levels of
BCAM1946, which codes for the RND transporter portion of
RND-9, were assessed. Data obtained revealed that rnd-9 gene
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was greatly and signiﬁcantly up-regulated in all the mutants
(P < 0.0001) in respect to the WT strain, the overexpression
ranging between 200-fold in SB6 and about 1000-fold in SB36
(Table 2).
In order to conﬁrm that the BCAM1946 overexpression
established by qRT-PCR was related to the production of
the corresponding protein, the membrane fractions of the
B. cenocepacia WT and mutant strains were extracted and
analyzed. The proteins present in this cellular fraction were
analyzed by SDS-PAGE and Coomassie blue staining, as
described in Supplementary data. A diﬀerence in the band
pattern was observed between the WT and the four mutants,
where a band of about 170 kDa was more abundant in the
mutants in respect to the J2315 strain (Supplementary Figure
S2). This diﬀerence was conﬁrmed by repeating the experiment
with independent cultures. The band was excised from the
acrylamide gel and identiﬁed by mass spectrometry. The band
was identiﬁed as BCAM1946, the inner membrane component
of RND-9 (Supplementary Table S3), which was shown to be
overexpressed by qRT-PCR.
Antibiotic Susceptibility of Mutant Strains and
of the RND-9 Deleted Strain
It is noteworthy that the overexpression of eﬄux pumps is
responsible for a resistance phenotype in bacteria, being these
transporters able to extrude diﬀerent compounds. In this way,
the MIC of diﬀerent antibiotics was assessed for the four
10126109 resistant strains. The mutant strains showed a 2–
16-fold increase in resistance toward all the compounds tested
(Table 1). In particular, all of them were twofold more resistant
to chloramphenicol, eightfold more resistant to ciproﬂoxacin,
levoﬂoxacin, norﬂoxacin, and sparﬂoxacin, and 16-fold more
resistant to nalidixic acid compared to the WT strain (Table 1).
SB36 mutant was 16-fold more resistant to levoﬂoxacin and
sparﬂoxacin (Table 1).
Although our previous ﬁnding suggested no correlation
between RND-9 and ciproﬂoxacin resistance in B. cenocepacia
(Buroni et al., 2014), being BCAM1948 a MerR transcriptional
regulator, it could control the expression of other genes encoding
both eﬄux pumps and/or involved in ciproﬂoxacin resistance.
To further assess whether RND-9 could be involved in
10126109 extrusion, the MIC of the compound was assessed also
for the RND-9 deleted strain. In this case, the MIC was twofold
lower respect to the WT.
Taken together these results conﬁrmed that the RND-9
overexpression is responsible for resistance to 10126109, and
TABLE 2 | BCAM1946 expression levels by quantitative reverse
transcription PCR (qRT-PCR) in B. cenocepacia WT (J2315) and mutated
strains.
B. cenocepacia strains BCAM1946 fold-change (±SD)
J2315 1.16 ± 0.85
SB5 855.97 ± 12.58
SB6 205.07 ± 16.30
SB34 469.22 ± 81.30
SB36 993.66 ± 72.99
suggested the involvement of this transporter in the 10126109
eﬄux.
Complementation
To ﬁnally show that the mutations found in BCAM1948
gene were responsible for the resistant phenotype of the four
B. cenocepacia mutants, SB5, SB34, and SB36 strains were
transformed by triparental conjugation with pSCrhaB2 vector
carrying aWT copy of BCAM1948. The expression of BCAM1948
was induced by adding 0.2% rhamnose to the growth medium
(Cardona and Valvano, 2005).
Subsequently, the MIC of the compounds to which the four
strains showed resistance, was assessed for the complemented
strains (Table 1). The values were compared to the mutants
transformed with the empty vector. Indeed, all the complemented
strains showed MIC values (including those of 10126109)
comparable to the B. cenocepacia J2315 strain (Table 1),
indicating that complementation occurred.
Also these data conﬁrmed the involvement of RND-9 in eﬄux-
mediated resistance to 10126109.
These results, together with the overexpression of BCAM1946
shown by quantitative RT-PCR and membrane fraction
extraction, indicate that BCAM1948 acts as a repressor for RND-
9. In fact, in the presence of a mutated regulator (strains SB5,
SB34, and SB36) or of an altered putative operator region (strain
SB6) the expression of the eﬄux pump was greatly increased. It
is noteworthy that the mutations located in the repressor coding
region lead to a greater overexpression of RND-9 compared to
the mutation located in the operator (SB6).
The MerR regulators have been originally described as
activators (Brown et al., 2003), even if a diﬀerent role has
been hypothesized and a double function previously reported
(Lee et al., 1993). Our results strongly suggest that MerR-
like regulators can act as repressors in B. cenocepacia, in
agreement with a recent work revealing their role as repressors
in Pseudomonas aeruginosa (Chambers and Sauer, 2013).
Discussion
It is noteworthy that unfortunately pharmaceutical industry is
not investing in drug discovery against neglected infections such
as those caused by B. cenocepacia, a dangerous CF pathogen.
CF is a rare disease, and B. cenocepacia infections only occur
in the 1–3% of patients. In this context, ﬁnding new molecules
active against B. cenocepacia is of great importance as it is
able to cause fatal infections which also lead the patient not to
be admitted in transplant lists (Noone, 2008; De Soyza et al.,
2010).
In this work, a compound belonging to the 2,1,3-
benzothiadiazol-5-yl family has been described as a promising
bactericidal anti-Burkholderia agent, being the MIC against
B. cenocepacia J2315 8 μg/ml. The compound has been shown
to be eﬀective also against B. cenocepacia clinical isolates and
Bcc belonging species, thus providing a good starting point
for pre-clinical trials. It is noteworthy that the compound is
not cytotoxic, nor mutagenic, suggesting its potential safety
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for future clinical trials on humans. The chemical structure of this
compound will be useful also for future research and structure-
activity relationship studies.
Even if there is not a formal eradication protocol
for Bcc infections, often combinations of two or three
drugs are administered, including nebulised tobramycin
(MIC = 256 μg/ml) with or without additional oral antibiotics,
such as minocycline (MIC = 16 μg/ml) or meropenem
(MIC = 64 μg/ml; Horsley et al., 2011). EUCAST guidelines
established that clinicians must continue to assess each patient
individually and that it is not currently possible to establish
MIC breakpoints for Bcc organisms3. In this context, the
availability of a new chemical structure, showing an MIC lower
respect to the currently used drugs, is a good and fundamental
starting point to work on, in order to ﬁnd new therapeutic
solutions.
Amechanism of resistance to this new compound, which relies
on the overexpression of RND-9 eﬄux pump, has been disclosed.
Evidences came from the whole genome sequences of four
resistant strains, showing mutations in the MerR transcriptional
regulator BCAM1948 and responsible for the overexpression of
the eﬄux pump both at the transcriptional and translational
levels. Moreover, MIC determination of diﬀerent compounds
plus the complementation of the mutated strains with aWT copy
of the gene conﬁrmed the prominent role of the eﬄux pump in
the resistance.
3 http://www.eucast.org/ﬁleadmin/src/media/PDFs/EUCAST_ﬁles/General_
documents/BCC_susceptibility_testing_130719.pdf
Our data support our previous studies on the role of
B. cenocepacia eﬄux transporters in drug resistance (Buroni et al.,
2009, 2014; Bazzini et al., 2011; Coenye et al., 2011; Scoﬀone
et al., 2014). Among 16 eﬄux systems encoded in the genome
of B. cenocepacia, only a few appear responsible for a resistant
phenotype (RND-3, RND-4, RND-9, and RND-10). In this way,
the use of new eﬄux inhibitors able to block these speciﬁc pumps
coupled to new drugs able to interfere with B. cenocepacia growth,
in order to avoid their extrusion, seems of primary importance in
order to ﬁght a main concern in Gram-negatives.
Acknowledgments
This work was supported by the Italian Cystic Fibrosis Research
Foundation (FFC project #10/2012 to G. R.; adopted by
Associazione Trentina FC onlus in ricordo di Zaira Tutino,
Gruppo di Sostegno FFC di Palermo - in ricordo di Elisa Pepe,
Delegazione FFC di Imola).
The authors are grateful to Dr. P. Drevinek (University
Hospital Motol, Charles University, Prague, Czech Republic) for
providing some of the B. cenocepacia clinical isolates.
Supplementary Material
The Supplementary Material for this article can be found
online at: http://journal.frontiersin.org/article/10.3389/fmicb.
2015.00815
References
Aaron, S. D., Ferris, W., Henry, D. A., Speert, D. P., and Macdonald, N. E. (2000).
Multiple combination bactericidal antibiotic testing for patients with cystic
ﬁbrosis infected with Burkholderia cepacia. Am. J. Respir. Crit. Care Med. 161,
1206–1212. doi: 10.1164/ajrccm.161.4.9907147
Bazzini, S., Udine, C., Sass, A., Pasca, M. R., Longo, F., Emiliani, G., et al. (2011).
Deciphering the role of RND eﬄux transporters in Burkholderia cenocepacia.
PLoS ONE 6:e18902. doi: 10.1371/journal.pone.0018902
Biasini, M., Bienert, S., Waterhouse, A., Arnold, K., Studer, G., Schmidt, T., et al.
(2014). SWISS-MODEL: modelling protein tertiary and quaternary structure
using evolutionary information. Nucleic Acids Res. 42, W252–W258. doi:
10.1093/nar/gku340
Brown, N. L., Stoyanov, J. V., Kidd, S. P., and Hobman, J. L. (2003). The MerR
family of transcriptional regulators. FEMS Microbiol. Rev. 27, 145–163. doi:
10.1016/S0168-6445(03)00051-2
Buroni, S., Matthijs, N., Spadaro, F., Van Acker, H., Scoﬀone, V. C., Pasca, M. R.,
et al. (2014). Diﬀerential role of RND eﬄux pumps in antimicrobial drug
resistance of sessile and planktonic Burkholderia cenocepacia cells. Antimicrob.
Agents Chemother. 58, 7424–7429. doi: 10.1128/AAC.03800-14
Buroni, S., Pasca, M. R., Flannagan, R. S., Bazzini, S., Milano, A., Bertani, I., et al.
(2009). Assessment of three Resistance-Nodulation-Cell Division drug eﬄux
transporters of Burkholderia cenocepacia in intrinsic antibiotic resistance. BMC
Microbiol. 9:200. doi: 10.1186/1471-2180-9-200
Cardona, S., and Valvano, M. A. (2005). An expression vector containing
a rhamnose-inducible promoter provides tightly regulated gene
expression in Burkholderia cenocepacia. Plasmid 54, 219–228. doi:
10.1016/j.plasmid.2005.03.004
Chambers, J. R., and Sauer, K. (2013). The MerR-like regulator BrlR impairs
Pseudomonas aeruginosa bioﬁlm tolerance to colistin by repressing PhoPQ.
J. Bacteriol. 195, 4678–4688. doi: 10.1128/JB.00834-13
Coenye, T., Van Acker, H., Peeters, E., Sass, A., Buroni, S., Riccardi, G., et al.
(2011). Molecular mechanisms of chlorhexidine tolerance in Burkholderia
cenocepacia bioﬁlms. Antimicrob. Agents Chemother. 55, 1912–1919. doi:
10.1128/AAC.01571-10
Cox, M. P., Peterson, D. A., and Biggs, P. J. (2010). SolexaQA: at-a-glance
quality assessment of Illumina second-generation sequencing data. BMC
Bioinformatics 11:485. doi: 10.1186/1471-2105-11-485
Craig, F. F., Coote, J. G., Parton, R., Freer, J. H., and Gilmour, N. J. (1989).
A plasmid which can be transferred between Escherichia coli and Pasteurella
haemolytica by electroporation and conjugation. J. Gen. Microbiol. 135, 2885–
2890. doi: 10.1099/00221287-135-11-2885
De Soyza, A., Meachery, G., Hester, K. L., Nicholson, A., Parry, G., Tocewicz, K.,
et al. (2010). Lung transplantation for patients with cystic ﬁbrosis and
Burkholderia cepacia complex infection: a single-center experience. J. Heart
Lung Transplant. 9, 1395–1404. doi: 10.1016/j.healun.2010.06.007
Dodge, J. A., Lewis, P. A., Stanton, M., and Wilsher, J. (2007). Cystic ﬁbrosis
mortality and survival in the UK: 1947-2003. Eur. Respir. J. 29, 522–526. doi:
10.1183/09031936.00099506
Hidalgo, E., Ding, H., and Demple, B. (1997). Redox signal transduction: mutations
shifting [2Fe-2S] centers of the SoxR sensor-regulator to the oxidized form. Cell
88, 121–129. doi: 10.1016/S0092-8674(00)81864-4
Higgins, C. F. (2007). Multiple molecular mechanisms for multidrug resistance
transporters. Nature 446, 749–757. doi: 10.1038/nature05630
Horsley, A., Webb, K., Bright-Thomas, R., Govan, J., and Jones, A. (2011).
Can early Burkholderia cepacia complex infection in cystic ﬁbrosis be
eradicated with antibiotic therapy? Front. Cell. Infect. Microbiol. 1:18. doi:
10.3389/fcimb.2011.00018
Koboldt, D. C., Chen, K., Wylie, T., Larson, D. E., McLellan, M. D.,
Mardis, E. R., et al. (2009). VarScan: variant detection in massively parallel
sequencing of individual and pooled samples. Bioinformatics 25, 2283–2285.
doi: 10.1093/bioinformatics/btp373
Frontiers in Microbiology | www.frontiersin.org 7 August 2015 | Volume 6 | Article 815
Scoffone et al. A new anti-B. cenocepacia compound
Lee, I. W., Levrelli, V., Park, S.-J., Totis, P. A., and Summers, A. O. (1993). In vivo
DNA-protein interactions at the divergent mercury resistance (mer) promoters.
J. Biol. Chem. 268, 2632–2639.
Lee, W. P., Stromberg, M. P., Ward, A., Stewart, C., Garrison, E. P.,
and Marth, G. T. (2014). MOSAIK: a hash-based algorithm for accurate
next-generation sequencing short-read mapping. PLoS ONE 9:e90581. doi:
10.1371/journal.pone.0090581
LiPuma, J. J. (2010). The changing microbial epidemiology in cystic ﬁbrosis. Clin.
Microbiol. 23, 299–323. doi: 10.1128/CMR.00068-09
Livak, K. J., and Schmittgen, T. D. (2001). Analysis of relative gene expression
data using real-time quantitative PCR and the 2−CT method. Methods 25,
402–408. doi: 10.1006/meth.2001.1262
Martin, A., Takiﬀ, H., Vandamme, P., Swings, J., Palomino, J. C., and Portaels, F.
(2006). A new rapid and simple colorimetric method to detect pyrazinamide
resistance in Mycobacterium tuberculosis using nicotinamide. J. Antimicrob.
Chemother. 58, 327–331. doi: 10.1093/jac/dkl231
NCCLS. (1999). Methods for Determining Bactericidal Activity of Antimicrobial
Agents: Approved Guideline M26-A. Wayne: National Committee for Clinical
Laboratory Standards.
Noone, P. G. (2008). Lung transplant and cystic ﬁbrosis: what’s new from the UK
and France? Thorax 63, 668-670. doi: 10.1136/thx.2008.099622
Perrin, E., Fondi, M., Papaleo, M. C., Maida, I., Emiliani, G., Buroni, S., et al.
(2013). A census of RND superfamily proteins in the Burkholderia genus. Future
Microbiol. 8, 923–937. doi: 10.2217/fmb.13.50
Quillardet, P., Huisman, O., D’Ari, R., and Hofnung, M. (1982). SOS chromotest,
a direct assay of induction of an SOS function in Escherichia coli K-12
to measure genotoxicity. Proc. Natl. Acad. Sci. U.S.A. 79, 5971–5975. doi:
10.1073/pnas.79.19.5971
Saiman, L., Siegel, J., and Cystic Fibrosis Foundation. (2003). Infection control
recommendations for patients with cystic ﬁbrosis: microbiology, important
pathogens, and infection control practices to prevent patient-to-patient
transmission. Infect. Control. Hosp. Epidemiol. 24, S6–S52. doi: 10.1086/
503485
Schmidtke, M., Schnittler, U., Jahn, B., Dahse, H., and Stelzner, A. (2001). A rapid
assay for evaluation of antiviral activity against coxsackie virus B3, inﬂuenza
virus A, and herpes simplex virus type 1. J. Virol. Methods 95, 133–143. doi:
10.1016/S0166-0934(01)00305-6
Scoﬀone, V. C., Spadaro, F., Udine, C., Makarov, V., Fondi, M., Fani, R.,
et al. (2014). Mechanism of resistance to an antitubercular 2-thiopyridine
derivative that is also active against Burkholderia cenocepacia. Antimicrob.
Agents Chemother. 58, 2415–2417. doi: 10.1128/AAC.02438-13
Silva, F., Lourenço, O., Queiroz, J. A., and Domingues, F. C. (2011). Bacteriostatic
versus bactericidal activity of ciproﬂoxacin in Escherichia coli assessed by ﬂow
cytometry using a novel far-red dye. J. Antibiot. (Tokyo) 64, 321–325. doi:
10.1038/ja.2011.5
Watanabe, S., Kita, A., Kobayashi, K., and Miki, K. (2008). Crystal structure of
the [2Fe-2S] oxidative-stress sensor SoxR bound to DNA. Proc. Natl. Acad. Sci.
U.S.A. 105, 4121–4126. doi: 10.1073/pnas.0709188105
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or ﬁnancial relationships that could
be construed as a potential conﬂict of interest.
Copyright © 2015 Scoﬀone, Ryabova, Makarov, Iadarola, Fumagalli, Fondi, Fani,
De Rossi, Riccardi and Buroni. This is an open-access article distributed under the
terms of the Creative Commons Attribution License (CC BY). The use, distribution or
reproduction in other forums is permitted, provided the original author(s) or licensor
are credited and that the original publication in this journal is cited, in accordance
with accepted academic practice. No use, distribution or reproduction is permitted
which does not comply with these terms.
Frontiers in Microbiology | www.frontiersin.org 8 August 2015 | Volume 6 | Article 815
